---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-058654"
form_type: "8-K"
ticker: "CYTK"
cik: "0001061983"
company_name: "CYTOKINETICS INC"
filed_at: "2024-05-13T23:59:59+00:00"
generated_at: "2026-06-02T01:50:08.603813+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Aficamten Phase 3 SEQUOIA-HCM meets primary endpoint: pVO2 improved 1.8 vs 0.0 mL/kg/min (p=0.000002)

## Summary
- All 10 prespecified secondary endpoints met, including KCCQ-CSS (+7 points, p<0.0001) and NYHA class improvement (34%, p<0.0001).
- Treatment reduced days eligible for septal reduction therapy by 78 days vs placebo (p<0.0001).
- No treatment interruptions due to low LVEF; serious adverse events 5.6% aficamten vs 9.3% placebo.
- Results presented at ESC Heart Failure 2024 and published in New England Journal of Medicine.
- Composite responder endpoint achieved by 42% aficamten vs 14% placebo (p<0.0001).

## SEC filing metadata
- accession: 0000950170-24-058654
- form_type: 8-K
- ticker: CYTK
- cik: 0001061983
- company_name: CYTOKINETICS INC
- filed_at: 2024-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1061983/000095017024058654/0000950170-24-058654-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1061983/000095017024058654/cytk-20240513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-058654
- JSON: https://secwatch.observer/filing/0000950170-24-058654.json
- Plain text: https://secwatch.observer/filing/0000950170-24-058654.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.